Stephen Uden - 14 Feb 2025 Form 4 Insider Report for Rallybio Corp (RLYB)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RLYB
Reported as of: 14 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2025, 19:30:54 UTC
Prior SEC filing: 16 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael Greco, Attorney-in-Fact

Key filing fact

Stephen Uden filed Form 4 for Rallybio Corp (RLYB) on 19 Feb 2025.

Key facts

This page summarizes Stephen Uden's Form 4 filing for Rallybio Corp (RLYB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2025, 19:30.

Change

Previous filing in this sequence was filed on 16 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLYB transaction Derivative

Option (Right to Buy)

Award

Transaction value: $0
Shares: +453,700
Change %
Price: $0.000000
Shares after: 453,700
Date: 14 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 453,700
Exercise price: $0.7600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 14, 2029.